Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...
Neuroscience
10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases
Garvan Institute's TenK10K Project Aims to Map 50 Million Human Cells from 10,000 People PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/...
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
New initiative aims to provide information and resources for teen mental health amidst rising public health concernsMALVERN, Pa., Aug. 01,...
Diagnostic Wearable Medical Devices Market size is set to grow by USD 8.76 billion from 2024-2028, Increasing prevalence of chronic diseases to boost the market growth, Technavio
NEW YORK, July 31, 2024 /PRNewswire/ -- The global diagnostic wearable medical devices market size is estimated to grow by USD...
Doctors Group Improves Employee Retention Rates with Empathy Training
Empathetics unveils new white paper BOSTON, July 30, 2024 /PRNewswire/ -- Empathetics, Inc. the pioneer in empathy training in healthcare,...
uMethod Health Collaborates with Linus Health to Streamline Digital Brain Health Assessment + Cognitive Care Planning
PHILADELPHIA, July 30, 2024 /PRNewswire/ -- uMethod Health, a pioneer in personalized cognitive care planning, has announced that it is...
Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors
MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for...
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
Conscious Collaboration for Global Transformation: The Chopra Foundation’s Sages & Scientists Symposium
The esteemed annual symposium explores the most urgent questions facing our future BOSTON, July 29, 2024 /PRNewswire/ -- The Chopra...
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July...
Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on...
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage...
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer’s Trial
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose...
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the...
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive...
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare...
Neurophet to launch total solution for AD treatments ‘Neurophet AQUA AD’ at AAIC 2024
- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE...
New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12
Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and...